



Press release
June 17, 2016
Gothenburg

XPS™ contract signed with leading hospital in Alabama

The XPS™ is the first sold to Alabama, USA. Delivery and installation of the XPS™ will take place in July 2016.

University of Alabama Birmingham is responsible for the only well-developed lung transplantation program in Alabama. The center has decided to purchase a XPS™ to establish an EVLP program and further develop the lung transplantation program.

XPS™ is the only CE-marked and FDA approved (Humanitarian Device Exemptions approval) integrated system on the market today which gives the user the flexibility to perform evaluation of lungs before transplantation through a standardized and simplified procedure. Use of XPS™ has shown good clinical results at 20 clinics in the US, many of which are national leaders in their field. Six XPS™ contracts have now been signed by European clinics, giving them access to the XPS™ system for lung transplantation, and the company notes continuing high interest for the XPS™ in the US and in Europe.

“We are delighted and proud that EVLP with XPS™ and STEEN Solution™ will be used for evaluating lungs for transplantation at the very well reputed University of Alabama Birmingham. This is the hospital performing lung transplantation in the state of Alabama, USA. The company sees a continued high interest from American and European clinics to set up XVIVO's XPS™ system to facilitate lung evaluation with the aim of using more of the donated lungs”, says Magnus Nilsson, CEO of XVIVO Perfusion.

June 17, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

The information was submitted for publication on June 17, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.